Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2019

01-10-2019 | Hypothyroidism | Review

Thyroid hormone therapy for hypothyroidism

Authors: Bernadette Biondi, David S. Cooper

Published in: Endocrine | Issue 1/2019

Login to get access

Abstract

The purpose of this article will be to review the basics of thyroid hormone therapy, including various thyroid hormone formulations, the institution and monitoring of thyroid hormone therapy, adverse effects of overtreatment, the management of patients with persistent symptoms despite normal thyroid function tests, and potential new innovations in thyroid hormone therapy. The conclusions support the necessity to personalize thyroid hormone replacement therapy in hypothyroid patients.
Literature
1.
A. Gruters, H. Krude, Detection and treatment of congenital hypothyroidism. Nat. Rev. Endocrinol. 18, 104–113 (2012)CrossRef
2.
W.M. Tunbridge, D.C. Evered, R. Hall et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin. Endocrinol. 7, 481–493 (1977)CrossRef
3.
J.G. Hollowell, N.W. Staehling, W.D. Flanders et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 489–499 (2002)CrossRefPubMed
4.
G.J. Canaris, N.R. Manowitz, G. Mayor, E.C. Ridgway, The Colorado thyroid disease prevalence study. Arch. Intern. Med. 160, 526–534 (2000)CrossRefPubMed
5.
J. Doucet, C. Trivalle, P. Chassagne et al. Does age play a role in clinical presentation of hypothyroidism? J. Am. Geriatr. Soc. 42, 984–986 (1994)CrossRefPubMed
6.
B. Biondi, A.R. Cappola, D.S. Cooper, Subclinical Hypothyroidism: A Review. JAMA 322, 153–160 (2019).CrossRefPubMed
7.
A.P. Bremner, P. Feddema, P.J. Leedman et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J. Clin. Endocrinol. Metab. 97, 1554–62 (2012)CrossRefPubMed
8.
T. Vadiveloo, P.T. Donnan, M.J. Murphy, G.P. Leese, Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the thyroid epidemiology, audit, and research study (TEARS). J. Clin. Endocrinol. Metab. 98, 1147–1153 (2013)CrossRefPubMed
9.
H.S. Ahn, D.W. Kim, Y.J. Lee, H.J. Baek, J.H. Ryu, Diagnostic accuracy of real-time sonography in differentiating diffuse thyroid disease from normal thyroid parenchyma: a multicenter study. AJR Am. J. Roentgenol. 211, 649–654 (2018)CrossRefPubMed
10.
O. Koulouri, C. Moran, D. Halsall, K. Chatterjee, M. Gurnell, Pitfalls in the measurement and interpretation of thyroid function tests. Best. Pract. Res. Clin. Endocrinol. Metab. 27, 745–762 (2013)CrossRefPubMedPubMedCentral
11.
N. Hattori, T. Ishihara, K. Yamagami, A. Shimatsu, Macro TSH in patients with subclinical hypothyroidism. Clin. Endocrinol. 83, 923–930 (2015)CrossRef
12.
J.R. Garber, R.H. Cobin, H. Gharib, American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults et al., Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22, 1200–1235 (2012).CrossRefPubMed
13.
J. Jonklaas, A.C. Bianco, A.J. Bauer, American Thyroid Association Task Force on Thyroid Hormone Replacement et al., Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid 24, 1670–751 (2014).CrossRefPubMedPubMedCentral
14.
B. Biondi, D.S. Cooper, The clinical significance of subclinical thyroid dysfunction. Endocr. Rev. 29, 76–131 (2008)CrossRefPubMed
15.
16.
N. Rodondi, W.P. den Elzen, D.C. Bauer, Thyroid Studies Collaboration et al., Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 304, 1365–1374 (2010).CrossRefPubMedPubMedCentral
17.
B. Gencer, T.H. Collet, V. Virgini, Thyroid Studies Collaboration et al., Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 126, 1040–1049 (2012).CrossRefPubMed
18.
19.
G. Brenta, M. Vaisman, J.A. Sgarbi et al. Task Force on Hypothyroidism of the Latin American Thyroid Society (LATS). Clinical practice guidelines for the management of hypothyroidism. Arq. Bras. Endocrinol. Metabol. 57, 265–291 (2013)
20.
G.E. Bekkering, T. Agoritsas, L. Lytvyn et al. Thyroid hormones treatment for subclinical hypothyroidism : a clinical practice guideline. BMJ 14(365), l2006 (2019)CrossRef
21.
J. Lazarus, R.S. Brown, C. Daumerie, A. Hubalewska-Dydejczyk, R. Negro, B. Vaidya,European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur. Thyroid J. 3, 76–94 (2014)CrossRefPubMedPubMedCentral
22.
E.K. Alexander, E.N. Pearce, G.A. Brent et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 27, 315–389 (2017)CrossRefPubMed
23.
M. Fleseriu, J.A. Hashim, N. Karavitaki et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 3888–3921 (2016)CrossRefPubMed
24.
25.
T.D. Hoang, C.H. Olsen, V.Q. Mai, P.W. Clyde, M.K. Shakir, Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism:a randomized, double-blind, crossover study. J. Clin. Endocrinol. Metab. 98, 1982–1990 (2013)CrossRefPubMed
26.
B. Biondi, L. Bartalena, L. Chiovato et al. “Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association”. J. Endocrinol. Investig. 39, 1465–1474 (2016)CrossRefPubMed
27.
J.I. Mechanick, E.M. Brett, A.B. Chausmer, R.A. Dickey, S. Wallach, American Association of Clinical Endocrinologists, American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr. Pract. 9, 417–470 (2003).CrossRefPubMed
28.
L.E. Braverman, S.H. Ingbar, K. Sterling, Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects. J. Clin. Investig. 49, 855–864 (1970)CrossRefPubMedPubMedCentral
29.
R. Vita, S. Benvenga, Tablet levothyroxine (l-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to l-T4 in soft gel capsule. Endocr. Pract. 20, e38–41 (2014)CrossRefPubMed
30.
C. Virili, P. Trimboli, F. Romanelli, M. Centanni, Liquid and softgel levothyroxine use in clinical practice: state of the art. Endocrine 54, 3–14 (2016)CrossRefPubMed
31.
J.V. Hennessey, A.O. Malabanan, B.R. Haugen, E.G. Levy, Adverse event reporting in patients treated with levothyroxine: results of the pharmacovigilance task force survey of the American Thyroid Association, American Association of Clinical Endocrinologists, and the Endocrine Society. Endocr. Pract. 16, 357–370 (2010)CrossRefPubMed
32.
L. Wartofsky, Levothyroxine: therapeutic use and regulatory issues related to bioequivalence. Expert Opin. Pharmacother. 3, 727–732 (2002)CrossRefPubMed
33.
F.S. Celi, M. Zemskova, J.D. Linderman et al. Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J. Clin. Endocrinol. Metab. 96, 3466–3474 (2011)CrossRefPubMedPubMedCentral
34.
W.M. Wiersinga, L. Duntas, V. Fadeyev, B. Nygaard, M.P. Vanderpump, ETA guidelines: the use of l-T4 + l-T3 in the treatment of hypothyroidism. Eur. Thyroid J. 1, 55–71 (2014)CrossRef
35.
L. Bartalena, E. Martino, A. Pacchiarotti et al. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. J. Clin. Endocrinol. Metab. 64, 849–855 (1987)CrossRefPubMed
36.
L. Persani, Clinical review: central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J. Clin. Endocrinol. Metab. 97, 3068–3078 (2012)CrossRefPubMed
37.
J. Jonklaas, Sex and age differences in levothyroxine dosage requirement. Endocr. Pract. 16, 71–79 (2010)CrossRefPubMed
38.
F. Santini, A. Pinchera, A. Marsili et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J. Clin. Endocrinol. Metab. 90, 124–127 (2005)CrossRefPubMed
39.
M. Devdhar, R. Drooger, M. Pehlivanova, G. Singh, J. Jonklaas, Levothyroxine replacement doses are affected by gender and weight, but not age. Thyroid 21, 821–827 (2011)CrossRefPubMedPubMedCentral
40.
V. Fonseca, M. Thomas, A. Katrak, P. Sweny, J.F. Moorhead, Can urinary thyroid hormone loss cause hypothyroidism? Lancet 24(8765), 475–476 (1991). 338CrossRef
41.
N.A. Junglee, M.F. Scanlon, D.A. Rees, Increasing thyroxine requirements in primary hypothyroidism: don't forget the urinalysis! J. Postgrad. Med. 52, 201–203 (2006)PubMed
42.
N. Jassam, T.J. Visser, T. Brisco et al. Consumptive hypothyroidism: a case report and review of the literature. Ann. Clin. Biochem. 48, 186–189 (2011)CrossRefPubMed
43.
J.W. De Groot, T.P. Links, W.T. van der Graaf, Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann. Oncol. 17, 1719–1720 (2006)CrossRefPubMed
44.
P. Kundra, K.D. Burman, The effect of medications on thyroid function tests. Med. Clin. North Am. 96, 283–295 (2012)CrossRefPubMed
45.
M. Skelin, T. Lucijanić, D. Amidžić Klarić et al. Factors affecting gastrointestinal absorption of levothyroxine: a review. Clin. Ther. 39, 378–403 (2017)CrossRefPubMed
46.
L. Liwanpo, J.M. Hershman, Conditions and drugs interfering with thyroxine absorption. Best. Pract. Res Clin. Endocrinol. Metab. 23, 781–792 (2009)CrossRefPubMed
47.
J.C. Morris, How do you approach the problem of TSH elevation in a patient on highdose thyroid hormone replacement? Clin. Endocrinol. 70, 671–673 (2009)CrossRef
48.
T.G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, J. Jonklaas, Timing of levothyroxine adminis-tration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94, 3905–3912 (2009)CrossRefPubMedPubMedCentral
49.
N. Bolk, T.J. Visser, J. Nijman et al. Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch. Intern. Med. 170, 1996–2003 (2010)CrossRefPubMed
50.
H.M. Robertson, A.K. Narayanaswamy et al. Factors contributing to high levothyroxine doses in primary hypothyroidism: an interventional audit of a large community database. Thyroid 24, 1765–1771 (2014)CrossRefPubMed
51.
M. Centanni, L. Gargano, G. Canettieri et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med. 354, 1787–1795 (2006)CrossRefPubMed
52.
S. Benvenga, L. Bartolone, M.A. Pappalardo et al. Altered intestinal absorption of l-thyroxine caused by coffee. Thyroid 18, 293–301 (2008)CrossRefPubMed
53.
P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97, E419–422 (2012)CrossRefPubMed
54.
M. Cellini, M.G. Santaguida, I. Gatto et al. Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine. J. Clin. Endocrinol. Metab. 99(8), E1454–1458 (2014)CrossRefPubMed
55.
S.K. Grebe, R.R. Cooke, H.C. Ford, J.N. Fagerström, D.P. Cordwell, N.A. Lever, G.L. Purdie, C.M. Feek, Treatment of hypothyroidism with once weekly thyroxine. J. Clin. Endocrinol. Metab. 82, 870–875 (1997)PubMed
56.
C. Virili, M. Centanni, Does microbiota composition affect thyroid homeostasis? Endocrine 49, 583–587 (2015)CrossRefPubMed
57.
A. Lobasso, L. Nappi, L. Barbieri et al. Severe hypothyroidism due to the loss of therapeutic efficacy of l-thyroxine in a patient with esophageal complication associated with systemic sclerosis. Front. Endocrinol. (Lausanne) 8, 241 (2017)CrossRef
58.
M. McMillan, K.S. Rotenberg, K. Vora et al. Comorbidities, concomitant medications, and diet as factors affecting. Levothyroxine therapy: results of the CONTROL surveillance project. Drugs R D 16, 53–68 (2016)CrossRefPubMed
59.
S.A. Irving, T. Vadiveloo, G.P. Leese, Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin. Endocrinol 82, 136–141 (2015)CrossRef
60.
M.G. Santaguida, C. Virili, S.C. Del Duca et al. Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. Endocrine 49, 51–57 (2015)CrossRefPubMed
61.
C. Virili, L. Giovanella, P. Fallahi et al. Levothyroxine therapy: changes of TSH levels by switching patients from tablet to liquid formulation. a systematic review and meta-analysis. Front. Endocrinol. 9, 10 (2018)CrossRef
62.
R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J. Clin. Endocrinol. Metab. 99, 4481–4486 (2014)CrossRefPubMed
63.
R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, A novel formulation of l-thyroxine (T4) reduces the problem of T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 43, 154–160 (2013)CrossRefPubMed
64.
C. Cappelli, I. Pirola, L. Daffini et al. A double-blind placebo-controlled trial of liquid thyroxine ingested at breakfast: results of the TICO study. Thyroid 26, 197–202 (2016)CrossRefPubMed
65.
P. Fierabracci, S. Martinelli, A. Tamberi et al. Weight loss and variation of levothyroxine requirements in hypothyroid obese patients after bariatric surgery. Thyroid 26, 499–503 (2016)CrossRefPubMed
66.
S. Gadiraju, C.J. Lee, D.S. Cooper, Levothyroxine dosing following bariatric surgery. Obes. Surg. 26, 2538–2542 (2016)CrossRefPubMed
67.
K.B. Ain, S. Refetoff, H.G. Fein, B.D. Weintraub, Pseudomalabsorption of levothyroxine. JAMA 266, 2118–1220 (1991)CrossRefPubMed
68.
D.J. Lips, M.T. van Reisen, V. Voigt, W. Venekamp, Diagnosis and treatment of pseudomalabsorption. Neth. J. Med. 62, 114–118 (2004)PubMed
69.
J.N. Walker, P. Shillo, V. Ibbotson et al. A thyroxine absorption test followed by weekly thyroxine administration: a method to assess non-adherence to treatment. Eur. J. Endocrinol. 168, 913–917 (2013)CrossRefPubMed
70.
S. Rangan, A.A. Tahrani, A.F. Macleod, P.K. Moulik, Once weekly thyroxine treatment as a strategy to treat non-compliance. Postgrad. Med J. 83(984), e3 (2007)CrossRefPubMed
71.
V. Eligar, P.N. Taylor, O.E. Okosieme, G.P. Leese, C.M. Dayan, Thyroxine replacement: a clinical endocrinologist's viewpoint. Ann. Clin. Biochem. 53(Pt 4), 421–433 (2016)CrossRefPubMed
72.
K. Andersson, A. Melander, C. Svensson, O. Lind, J.L. Nilsson, Repeat prescriptions: refill adherence in relation to patient and prescriber characteristics, reimbursement level and type of medication. Eur. J. Public Health 15, 621–626 (2005)CrossRefPubMed
73.
L.L. Somwaru, A.M. Arnold, N. Joshi, L.P. Fried, A.R. Cappola, High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J. Clin. Endocrinol. Metab. 94, 1342–1345 (2009)CrossRefPubMedPubMedCentral
74.
C.T. Sawin, T. Herman, M.E. Molitch, M.H. London, S.M. Kramer, Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am. J. Med. 75, 206–209 (1983)CrossRefPubMed
75.
T.O. Obisesan, M.H. Aliyu, V. Bond, R.G. Adams, A. Akomolafe, C.N. Rotimi, Ethnic and age-related fat free mass loss in older Americans: the Third National Health and Nutrition Examination Survey (NHANES III). BMC Public Health 5, 41 (2005)CrossRefPubMedPubMedCentral
76.
M.T. Hays, K.R. Nielsen, Human thyroxine absorption: age effects and methodological analyses. Thyroid 4, 55–64 (1994)CrossRefPubMed
77.
M. Centanni, M. Marignani, L. Gargano et al. Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. Arch. Intern Med. 159, 1726–1730 (1999)CrossRefPubMed
78.
S. Checchi, A. Montanaro, L. Pasqui et al. l-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J. Clin. Endocrinol. Metab. 93, 465–469 (2008)CrossRefPubMed
79.
J.J. Scargill, M. Livingston, D. Holland, C.J. Duff, A.A. Fryer, A.H. Heald, Monitoring thyroid function in patients on levothyroxine. Assessment of Conformity to National Guidance and Variability in Practice. Exp. Clin. Endocrinol. Diabetes 125, 625–633 (2017)CrossRefPubMed
80.
U.M. Kabadi, Variability of l-thyroxine replacement dose in elderly patients with primary hypothyroidism. J. Fam. Pract. 24, 473–477 (1987)PubMed
81.
P.N. Taylor, C. Minassian, R.A. Rehman et al. TSH levels and risk of miscarriage in women on long-term levothyroxine: a community-based study. J. Clin. Endocrinol. Metab. 99, 3895–902 (2014)CrossRefPubMed
82.
R.W. Flynn, S.R. Bonellie, R.T. Jung, T.M. MacDonald, A.D. Morris, G.P. Leese, Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J. Clin. Endocrinol. Metab. 95, 186–193 (2010)CrossRefPubMed
83.
E.N. Klein Hesselink, M.S. Klein Hesselink, G.H. de Bock et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J. Clin. Oncol. 31, 4046–4053 (2013)CrossRefPubMed
84.
M.R. Blum, D.C. Bauer, T.H. Collet, H.A. Fink,Thyroid Studies Collaboration et al., Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313, 2055–2065 (2015).CrossRefPubMedPubMedCentral
85.
K.H. Winther, P. Cramon, T. Watt et al. Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy. PLoS ONE 11, e0156925 (2016)CrossRefPubMedPubMedCentral
86.
87.
S.J. Peterson, A.R. Cappola, M.R. Castro et al. Degrees of satisfaction and coexistent diseases in those responding to a survey exploring perceptions about treatment of hypothyroidism. Thyroid 28, 707–721 (2018)CrossRefPubMedPubMedCentral
88.
L.F. Michaelsson, B.B. Medici, J.L. la Cour et al. Treating hypothyroidism with thyroxine/triiodothyronine combination therapy in Denmark: following guidelines or following trends?. Eur. Thyroid J. 4, 174–180 (2015)CrossRefPubMedPubMedCentral
89.
90.
O. Okosieme, J. Gilbert, P. Abraham et al. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clin. Endocrinol. 84, 799–808 (2016)CrossRef
91.
J. Jonklaas, B. Davidson, S. Bhagat, S.J. Soldin, Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 299, 769–777 (2008)CrossRefPubMed
92.
M. Ito, A. Miyauchi, S. Morita T et al. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur. J. Endocrinol. 167, 373–378 (2012)CrossRefPubMed
93.
J. Jonklaas, Persistent hypothyroid symptoms in a patient with a normal thyroid stimulating hormone level. Curr. Opin. Endocrinol. Diabetes Obes. 24, 356–363 (2017)CrossRefPubMedPubMedCentral
94.
A.C. Biancom, B.W. Kim, Deiodinases: implications of the local control of thyroid hormone action. J. Clin. Investig. 116, 2571–2579 (2006)CrossRef
95.
96.
B.C. Appelhof, R.P. Peeters, W.M. Wiersinga et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3'-triiodothyronine therapy. J. Clin. Endocrinol. Metab. 90, 6296–6299 (2005)CrossRefPubMed
97.
A. Carle, J. Faber, R. Steffensen, P. Laurberg, B. Nygaard, Hypothyroid patients encoding combined MCT10 and DIO2 gene polymorphisms may prefer l-T3 + l-T4 combination treatment—data using a blind, randomized clinical study. Eur. Thyroid J. 6, 143–151 (2017)CrossRefPubMedPubMedCentral
98.
W.M. Wiersinga, Therapy of endocrine disease: T4 + T3 combination therapy: is there a true effect? Eur. J. Endocrinol. 177, R287–R296 (2017)CrossRefPubMed
99.
J.C. Galofré, J.J. Díez, D.S. Cooper, Thyroid dysfunction in the era of precision medicine. Endocrinol. Nutr. 63(7), 354–363 (2016)CrossRefPubMed
100.
P.W. Ladenson, Precision medicine comes to thyroidology. J. Clin. Endocrinol. Metab. 101, 799–803 (2016)CrossRefPubMed
Metadata
Title
Thyroid hormone therapy for hypothyroidism
Authors
Bernadette Biondi
David S. Cooper
Publication date
01-10-2019
Publisher
Springer US
Published in
Endocrine / Issue 1/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-02023-7

Other articles of this Issue 1/2019

Endocrine 1/2019 Go to the issue

Review

Thyroid hormone metabolites and analogues

Review

Thyroid hormone therapy in differentiated thyroid cancer

Mini Review

Thyroxine and treatment of hypothyroidism: seven decades of experience

Review

Novel uses of thyroid hormones in cardiovascular conditions

Review

Novel thyroxine formulations: a further step toward precision medicine

Review

Thyroid hormone therapy of hypothyroidism in pregnancy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits